Anticoagulation Management Post Pulmonary Embolism.

Humans Pulmonary Embolism / drug therapy Anticoagulants / adverse effects Risk Factors Treatment Outcome Blood Coagulation / drug effects Administration, Oral Risk Assessment Hemorrhage / chemically induced Vitamin K / antagonists & inhibitors Clinical Decision-Making
anticoagulation deep vein thrombosis direct oral anticoagulants low molecular weight heparin pulmonary embolus revascularization unfractionated heparin venotonics venous thromboembolism

Journal

Methodist DeBakey cardiovascular journal
ISSN: 1947-6108
Titre abrégé: Methodist Debakey Cardiovasc J
Pays: United States
ID NLM: 101508600

Informations de publication

Date de publication:
2024
Historique:
received: 09 01 2024
accepted: 27 02 2024
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 20 5 2024
Statut: epublish

Résumé

Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for therapeutic adjustment or manipulation is important. The preferred choice of anticoagulation management includes direct oral anticoagulants. Vitamin K antagonists and low-molecular-weight heparin are preferred in special populations or selected patients such as breastfeeding mothers, those with end-stage renal disease, or obese patients, among others. This article reviews the primary and longer-term considerations for anticoagulation management in patients with PE and highlights special patient populations and risk factor considerations.

Identifiants

DOI: 10.14797/mdcvj.1338 PMID: 38765210 PMC: PMC11100539
pubmed: 38765210
doi: 10.14797/mdcvj.1338
pmc: PMC11100539
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-35

Informations de copyright

Copyright: © 2024 The Author(s).

Déclaration de conflit d'intérêts

The author has no competing interests to declare.

Auteurs

Joseph J Naoum (JJ)

Houston Methodist Hospital Clear Lake, Nassau Bay, Texas, US.
Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, US.
ORCID: 0009-0003-1501-0842

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Embolie et thrombose › Embolie › Embolie pulmonaire › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents hématologiques › Anticoagulants › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiogiques du sang › Hémostase › Coagulation sanguine › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Hémorragie › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Naphtalènes › Naphtoquinones › Vitamine K › Anticoagulation Management Post Pulmonary Embolism.
questionsmedicales.fr › Diagnostic › Prise de décision clinique › Anticoagulation Management Post Pulmonary Embolism.